Results 11 to 20 of about 10,843,123 (260)

Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease [PDF]

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016
AbstractIntroductionSolanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD).MethodsPatients (n = 2042) with mild and moderate AD were randomized 1:1 to 400‐mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open‐label ...
Jérôme Barakos
exaly   +4 more sources

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.
Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A. Ljubenkov, Karine Provost, David Soleimani‐Meigooni, Amelia Strom, Elena Tsoy, Gil D. Rabinovici, Adam L. Boxer   +10 more
doaj   +7 more sources

Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy.

Frontiers in Neurology, 2015
Amyloid Related Imaging Abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer’s disease (AD).
Jacopo C. DiFrancesco, Jacopo C. DiFrancesco, Martina eLongoni, Martina eLongoni, Fabrizio ePiazza, Fabrizio ePiazza, Fabrizio ePiazza   +6 more
doaj   +4 more sources

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice [PDF]

American Journal of Neuroradiology, 2022
Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities. Amyloid-related imaging abnormalities result from treatment-related loss of vascular integrity and may occur in 2 forms.
P.M. Cogswell, J.A. Barakos, F. Barkhof, T.S. Benzinger, C.R. Jack, T.Y. Poussaint, C.A. Raji, V.K. Ramanan, C.T. Whitlow   +8 more
core   +6 more sources

Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease. [PDF]

Brain Commun
Alzheimer’s disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions.
Aljuhani M, Ashraf A, Edison P.
europepmc   +4 more sources

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) are commonly observed with anti‐amyloid therapies in Alzheimer's disease.
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, Carsten Hofmann, Dominik Lott, Szofia Bullain, Paul Delmar, Gregory Klein, Marco Lyons, Fabrizio Piazza, Roxana O. Carare, Norman A. Mazer   +11 more
doaj   +2 more sources

Amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease: from pathophysiology to individualized risk assessment [PDF]

Alzheimer’s Research & Therapy
Monoclonal antibodies targeting amyloid-β are the first approved disease-modifying treatment for Alzheimer’s disease. While amyloid-targeting therapies mitigate the progression of cognitive decline in early-stage Alzheimer’s disease, they are associated ...
Jonathan Merkel, Robert Perneczky, Frank Jessen, Lutz Frölich, Olav Jansen, Sönke Peters, Daniela Berg, Jörg B. Schulz, Thorsten Bartsch   +8 more
doaj   +2 more sources

Artificial Intelligence-Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls. [PDF]

AJNR Am J Neuroradiol
The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). We report a literature review and early quality-assurance experience with an FDA-cleared decision support artificial ...
Petrella JR, Liu AJ, Wang LA, Doraiswamy PM.   +3 more
europepmc   +3 more sources

Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele

Chronic Diseases and Translational Medicine
Monoclonal antibodies (mAbs) have made significant progress in the treatment of Alzheimer's disease (AD). However, mAbs are associated with adverse effects, including Amyloid‐Related Imaging Abnormality (ARIA), which manifests as edema or effusion (ARIA ...
Valentinus Besin, Farizky Martriano Humardani, Fenny Lanawati Yudiarto, Paulus Anam Ong, Sulistyo Emantoko Dwi Putra, Ratih Asmana Ningrum   +5 more
doaj   +4 more sources

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Scientific Reports
Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with edema (ARIA-E). We
Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Patrik Nygren, Nicolas Fritz, Olof Zachrisson, Adeline Rachalski, Anne-Sophie Svensson, Emily Button, Giacomo Dentoni, Gunilla Osswald, Lars Lannfelt, Christer Möller   +12 more
doaj   +2 more sources